Search

News Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A

GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol, has demonstrated prophylactic efficacy in patients with severe hemophilia A aged over 12. This product is administered only once every 4 days. In addition to a comparable reduction in the annual bleed rate to standard FVIII prophylaxis products, it has also shown sufficient efficacy in bleeding treatment and a minimal risk of inhibitory antibody formation.

Source: Hemophilia with Movement 28. 1. 2021

News Heart Failure in the Light of New ESC Guidelines

Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.

Source: Heart Failure 27. 10. 2021

News Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children

Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with deficits in executive functions. An analysis recently published in the journal Epilepsy & Behavior assessed the impact of fenfluramine therapy on executive functions in preschool children with this condition.

Source: Rare Diseases in Neurology 10. 10. 2023

News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy

New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.

Source: Hemophilia 18. 3. 2020

News How to Improve Diabetic Adherence?

The dream of every doctor is a conscientious patient who follows the prescribed treatment and reports any potential problems in a timely manner. But where can such a patient be found?

Source: Diabetes 7. 5. 2020

News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role

The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.

Source: Hematologic Malignancies 10. 2. 2022

News Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients

Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis strategies have been studied in morbidly obese patients; a recently published study compared the efficacy and safety of high doses of enoxaparin and unfractionated heparin.

Source: Thromboprophylaxis 28. 1. 2020

News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?

A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.

Source: Thromboprophylaxis 8. 4. 2020

News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction

Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.

Source: Diabetes 29. 10. 2021

News Hemophilia and Intensive Physical Activity Are Not Mutually Exclusive −⁠ Case Report of a Top Athlete

Traditionally, many doctors have been reluctant to allow men with hemophilia to engage in more intense physical activity, mainly due to concerns about bleeding caused by overexertion or injury. Today's prophylactic modalities, however, allow for prevention to be set in such a way that the risk of bleeding is significantly reduced. Modern treatment thus brings hope for hemophiliacs to participate in some sports that were previously not recommended. In addition to effective prophylaxis, appropriate training activities, developed with the participation of a physiotherapist and sports doctor, are also crucial.

Source: Hemophilia with Movement 25. 2. 2021

News Therapy Change from Adalimumab to Baricitinib in Patients with Rheumatoid Arthritis

The aim of the presented analysis of data from the RA-BEAM study was to evaluate the clinical response of patients who were switched to baricitinib during the study due to an inadequate response to adalimumab.

Source: Biological Treatment 30. 3. 2020

News Effect of Combination Therapy on Symptoms of Allergic Rhinitis

The aim of the study presented below by authors from the USA was to evaluate the efficacy, safety, and tolerability of treatment with the nasal spray GSP301 containing a fixed combination of active ingredients, compared to placebo and monotherapies during a 14-day therapy in adult and adolescent patients with allergic rhinitis.

Source: Life Without Allergic Rhinitis 24. 3. 2022

News Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression

Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.

Source: Oncological Treatment 21. 11. 2022

News Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU

In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil was evaluated in patients with complicated skin and soft tissue infections (cSSTI) admitted to the intensive care unit (ICU), and its effectiveness was compared with patients with the same diagnosis and treatment who did not require ICU admission.

Source: Anti-Infectives 17. 12. 2020

News Monotherapy with Bimatoprost in Patients with Glaucoma and Ocular Hypertension

Can monotherapy with bimatoprost be sufficiently effective in controlling intraocular pressure in non-responders to previous treatments? This is the question posed by British researchers in the presented study.

Source: Treatment of Glaucoma 4. 5. 2020